Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan

References

• Brown P. Effective treatments for mental illness not being used, WHO says. BMJ 2001; 323: 769
   Web of Science ®Google Scholar
• Demyttenaere K, Bruffaerts R, Posada-Villa J, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004; 291: 2581–2590
   PubMed Web of Science ®Google Scholar
• Kawakami N, Takeshima T, Ono Y, et al. Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: preliminary finding from the World Mental Health Japan Survey 2002–2003. Psychiatry Clin Neurosci 2005; 59: 441–452
   PubMed Web of Science ®Google Scholar
• Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003; 183: 514–519
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405–418
   PubMed Web of Science ®Google Scholar
• Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7: 191–195
   PubMed Web of Science ®Google Scholar
• Ministry of Health Labour and Welfare of Japan. White paper on the Labour Economy Tokyo: Ministry of Health Labour and Welfare of Japan, 2005.
   Google Scholar
• Borghi J, Guest JF. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. Eur Psychiatry 2000; 15: 378–387
   PubMed Web of Science ®Google Scholar
• Brown MC, Nimmerrichter AA, Guest JF. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria. Eur Psychiatry 1999; 14: 230–244
   PubMed Web of Science ®Google Scholar
• Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001; 4: 16–31
   PubMedGoogle Scholar
• Forder J, Kavanagh S, Fenyo A. A comparison of the cost-effectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996; 38: 97–111
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Mental Health Commissioned by NICE. Management of depression in primary and secondary care, National Clinical Practice Guideline Number 23 London: National Collaborating Centre for Mental Health, 2004.
   Google Scholar
• Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression. Br J Psychiatry 1997; 171: 328–334
   PubMed Web of Science ®Google Scholar
• Scott C, Tacchi MJ, Jones R, Scott J. Acute and one-year outcome of a randomised controlled trial of brief cognitive therapy for major depressive disorder in primary care. Br J Psychiatry 1997; 171: 131–134
   PubMed Web of Science ®Google Scholar
• Thompson LW, Coon DW, Gallagher-Thompson D, Sommer BR, Koin D. Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression. Am J Geriatr Psychiatry 2001; 9: 225–240
   PubMed Web of Science ®Google Scholar
• Keller MB, McCullough JP, Klein DN, et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342: 1462–1470
   PubMed Web of Science ®Google Scholar
• Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Cognitive therapy and pharmacotherapy. singly and together in the treatment of depression. Arch Gen Psychiatry 1984; 41: 33–41
   PubMed Web of Science ®Google Scholar
• Scott J, Palmer S, Paykel E, Teasdale J, Hayhurst H. Use of cognitive therapy for relapse prevention in chronic depression. Cost-effectiveness study. Br J Psychiatry 2003; 182: 221–227
   PubMed Web of Science ®Google Scholar
• Simon J, Pilling S, Burbeck R, Goldberg D. Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline. Br J Psychiatry 2006; 189: 494–501
   PubMed Web of Science ®Google Scholar
• Blackburn IM, Eunson KM, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. J Affect Disord 1986; 10: 67–75
   PubMed Web of Science ®Google Scholar
• Simons AD, Murphy GE, Levine JL, Wetzel RD. Cognitive therapy and pharmacotherapy for depression. Sustained improvement over one year. Arch Gen Psychiatry 1986; 43: 43–48
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ, Howland RH, et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002; 59: 233–239
   PubMed Web of Science ®Google Scholar
• Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 1998; 48: 25–36
   PubMed Web of Science ®Google Scholar
• Igaku Tushinsya. Quick reference to tariff for health care services Tokyo: Igaku tushinsya, 2005.
   Google Scholar
• Yakugyou Kenkyuukai. Dictionary for medicines covered by health insurance Tokyo: Jihou, 2005.
   Google Scholar
• Cabinet Office GoJ Estimates of GDP 2005 Tokyo: Cabinet Office, Government of Japan, 2005.
   Google Scholar
• Ministry of Health Labour and Welfare of Japan. Patient survey Tokyo: Ministry of Health Labour and Welfare of Japan, 2005.
   Google Scholar
• Ministry of Internal Affairs and Communications of Japan. Labour force survey Tokyo: Ministry of Internal Affairs and Communications of Japan, 2005.
   Google Scholar
• Ohkusa Y, Sugawara T. Research for willingness to pay for one QALY gain. J Health Care Soc 2006; 16: 157–165
   Google Scholar
• Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS. The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med 2001; 43: 218–325
   PubMed Web of Science ®Google Scholar
• Knapp M. Hidden costs of mental illness. Br J Psychiatry 2003; 183: 477–478
   PubMed Web of Science ®Google Scholar
• Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andrews G. The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry 2004; 61: 1097–1103
   PubMed Web of Science ®Google Scholar
• Miller IW, Norman WH, Keitner GI. Cognitive-behavioral treatment of depressed inpatients: six- and twelve-month follow-up. Am J Psychiatry 1989; 146: 1274–1279
   PubMed Web of Science ®Google Scholar
• Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry 2004; 184: 393–403
   PubMed Web of Science ®Google Scholar
• Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665–673
   PubMed Web of Science ®Google Scholar
• Woods SW, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. Br J Psychiatry 1997; 170: 257–263
   PubMed Web of Science ®Google Scholar